利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.026 秒)

    Method for preparing high molecular weight meningococcal Group C vaccine
    2.
    发明授权
    Method for preparing high molecular weight meningococcal Group C vaccine 失效
    制备高分子量脑膜炎球菌C组疫苗的方法

    公开(公告)号：US4123520A

    公开(公告)日：1978-10-31

    申请号：US820665

    申请日：1977-08-01

    申请人： Arpi Hagopian ,  Dennis J. Carlo ,  Thomas H. Stoudt

    发明人： Arpi Hagopian ,  Dennis J. Carlo ,  Thomas H. Stoudt

    IPC分类号： C12P19/04 ,  A61K39/095 ,  A61K39/02

    CPC分类号： A61K39/095

    摘要： A vaccine against Group C meningococcal meningitis consisting of a polysaccharide of which at least 80% by weight has a molecular weight in excess of 1,000,000 daltons is prepared. The polysaccharide was isolated from Group C hexadecyl trimethylammonium bromide cell paste with 1.0M CaCl.sub.2 extraction and purified by phenol extraction, ultracentrifugation at 100,000 g. and ethanol fractionation (30%-45% v/v in ethanol).

    摘要翻译： 制备针对C组脑膜炎球菌性脑膜炎的疫苗，其由至少80重量％的分子量超过1,000,000道尔顿的多糖组成。 从C组十六烷基三甲基溴化铵细胞糊中分离多糖，用1.0M CaCl 2萃取，通过苯酚提取纯化，用100,000g超速离心。 和乙醇分馏（30％-45％v / v在乙醇中）。

    High molecular weight meningococcal group C vaccine and method for preparation thereof
    4.
    发明授权
    High molecular weight meningococcal group C vaccine and method for preparation thereof 失效
    高分子量脑膜炎球菌C组疫苗及其制备方法

    公开(公告)号：US4235994A

    公开(公告)日：1980-11-25

    申请号：US919359

    申请日：1978-06-26

    申请人： Thomas H. Stoudt ,  Dennis J. Carlo ,  Arpi Hagopian

    发明人： Thomas H. Stoudt ,  Dennis J. Carlo ,  Arpi Hagopian

    IPC分类号： A61K39/095 ,  C08B37/00

    CPC分类号： A61K39/095 ,  Y10S514/898

    摘要： A vaccine against Group C meningococcal meningitis consisting of a polysaccharide of which at least 80% by weight has a molecular weight in excess of 1,000,000 daltons is prepared. The polysaccharide was isolated from Group C hexadecyl trimethylammonium bromide cell paste with 1.0M CaCl.sub.2 extraction and purified by phenol extraction, ultracentrifugation at 100,000 g. and ethanol fractionation (30%-45% v/v in ethanol).

    摘要翻译： 制备针对C组脑膜炎球菌性脑膜炎的疫苗，其由至少80重量％的分子量超过1,000,000道尔顿的多糖组成。 从C组十六烷基三甲基溴化铵细胞糊中分离多糖，1.0M CaCl 2萃取，苯酚提取纯化，超速离心10万g。 和乙醇分馏（30％-45％v / v在乙醇中）。

    Prevention and treatment of retroviral disease
    5.
    发明授权
    Prevention and treatment of retroviral disease 失效
    预防和治疗逆转录病毒病

    公开(公告)号：US5895650A

    公开(公告)日：1999-04-20

    申请号：US467334

    申请日：1995-06-05

    申请人： Jonas Salk ,  Dennis J. Carlo

    发明人： Jonas Salk ,  Dennis J. Carlo

    IPC分类号： A61M1/36 ,  A61P31/18 ,  C07K14/16 ,  C07K1/00 ,  A61K39/00 ,  A61K39/38 ,  C12N7/00

    CPC分类号： C07K14/005 ,  A61M1/3687 ,  C12N2740/16122 ,  Y10S530/826

    摘要： The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. There is also provided a vaccine effective against HIV. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce immunoprotective factors protective against progression of the infection. In another aspect, the vaccine is useful for vaccinating an individual not previously infected with HIV in order to prevent subsequently acquired infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce is antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.

    摘要翻译： 本发明提供含有不含外包膜蛋白或含有从逆转录病毒分离的选定抗原的逆转录病毒颗粒的非感染性免疫治疗剂。 还提供了有效防治艾滋病毒的疫苗。 一方面，免疫原可用于免疫先前被包括HIV的逆转录病毒感染的个体，以便诱导保护免受感染进展的免疫保护因子。 另一方面，疫苗可用于接种以前未感染HIV的个体，以防止随后获得性感染。 另一方面，提供了使非感染性病毒免疫原呈递的方法。 免疫原也可以用于在感染逆转录病毒（包括HIV）的个体中产生单独的或与主动免疫治疗联合的被动免疫治疗的抗体，优选那些对除了外包膜以外的逆转录病毒基因产物具有低水平抗体的那些个体。

    Prevention and treatment of retroviral disease
    6.
    发明授权
    Prevention and treatment of retroviral disease 失效

    公开(公告)号：US5885578A

    公开(公告)日：1999-03-23

    申请号：US469739

    申请日：1995-06-05

    申请人： Jonas Salk ,  Dennis J. Carlo

    发明人： Jonas Salk ,  Dennis J. Carlo

    IPC分类号： A61M1/36 ,  A61P31/18 ,  C07K14/16 ,  C12N7/00 ,  A61K39/12 ,  A61K39/21 ,  C07K1/00

    CPC分类号： C07K14/005 ,  A61M1/3687 ,  C12N2740/16122 ,  Y10S530/826

    摘要： The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. There is also provided a vaccine effective against HIV. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce immunoprotective factors protective against progression of the infection. In another aspect, the vaccine is useful for vaccinating an individual not previously infected with HIV in order to prevent subsequently acquired infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.

    Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations
    10.
    发明授权
    Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations 失效
    针对由特定T细胞群体的致病反应引起的疾病的抗独特型疫苗接种

    公开(公告)号：US6007815A

    公开(公告)日：1999-12-28

    申请号：US332428

    申请日：1994-10-31

    申请人： Mark D. Howell ,  Steven W. Brostoff ,  Dennis J. Carlo

    发明人： Mark D. Howell ,  Steven W. Brostoff ,  Dennis J. Carlo

    IPC分类号： A61K39/00 ,  A61P37/06 ,  C07K14/725 ,  A61K39/395 ,  C07K16/42

    CPC分类号： C07K14/7051 ,  A61K2039/53 ,  A61K39/00

    摘要： The present invention provides vaccines and a means of vaccinating a host so as to prevent or control specific T cell mediated pathologies. The vaccine is composed of anti-idiotypic antibodies which are internal images of a segment of the T cell receptor (TCR) present on the surface of the pathogenic T cells. The vaccine is administered to the host in a manner that induces an immune response directed against the TCR of pathologic T cell. This immune response down regulates or deletes the pathogenic T cells, thus ablating the disease pathogenesis. Means of determining an appropriate amino acid sequence for such a vaccine are also provided.

    摘要翻译： 本发明提供疫苗和疫苗接种宿主的方法，以便预防或控制特定的T细胞介导的病理学。 疫苗由抗独特型抗体组成，其是存在于病原性T细胞表面上的T细胞受体（TCR）区段的内部图像。 以诱导针对病理T细胞的TCR的免疫应答的方式将疫苗施用于宿主。 这种免疫应答下调调节或去除病原性T细胞，从而消除疾病的发病机制。 还提供了确定这种疫苗的适当氨基酸序列的方法。